The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study.
D. E. Rathkopf
No relevant relationships to disclose
D. C. Danila
No relevant relationships to disclose
M. J. Morris
No relevant relationships to disclose
S. F. Slovin
No relevant relationships to disclose
L. S. Borwick
No relevant relationships to disclose
L. Momen
No relevant relationships to disclose
T. Curley
No relevant relationships to disclose
G. Arauz
No relevant relationships to disclose
S. M. Larson
No relevant relationships to disclose
M. Fleisher
No relevant relationships to disclose
N. Rosen
No relevant relationships to disclose
H. I. Scher
No relevant relationships to disclose